Compare Amylx Pharmaceuticals Inc (AMLX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs TKO Group Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.62 (market cap $2.64B), while TKO Group Holdings Inc trades at $195.51 (market cap $14.24B). The key difference: TKO Group Holdings Inc is far larger — about 5.4× Amylx Pharmaceuticals Inc's market cap, and TKO Group Holdings Inc pays a 1.6% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TKO | |
|---|---|---|
Market Cap | $2.64B | $14.24B |
Sector | Health | Technology |
52-Week High | $24.19 | $224.96 |
52-Week Low | $7.82 | $176.49 |
Enterprise Value | $2.39B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
TKO trades at $194.10, up 2.47% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed revenue growth of 18% year-over-year to $1.55 billion, though EPS of $1.34 missed estimates. The company raised full-year guidance, reflecting confidence in media rights and live events. Valuation metrics like a P/E of 68.33 appear elevated relative to earnings.
The outlook is positive given raised guidance and dominant market position in sports entertainment, but high valuation and recent earnings misses pose risks. Upside to the consensus price target of $228.17 suggests potential growth, dependent on execution of growth initiatives and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
